Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS - POTENTIAL IN THE TREATMENT OF PSYCHIATRIC-DISORDERS
Autore:
STEFANSKI R; GOLDBERG SR;
Indirizzi:
NIDA,PRECLIN PHARMACOL LAB,NIH,INTRAMURAL RES PROGRAM,POB 5180 BALTIMORE MD 21224
Titolo Testata:
CNS DRUGS
fascicolo: 5, volume: 7, anno: 1997,
pagine: 388 - 409
SICI:
1172-7047(1997)7:5<388:S5RA-P>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSESSIVE-COMPULSIVE DISORDER; GENERALIZED ANXIETY DISORDER; MEDIAL PREFRONTAL CORTEX; ELEVATED PLUS-MAZE; SLOW-WAVE SLEEP; CHRONIC-SCHIZOPHRENIC PATIENTS; NEUROLEPTIC INDUCED AKATHISIA; ANTI-DEPRESSANT TREATMENT; RAT STOMACH FUNDUS; DOUBLE-BLIND TRIAL;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
224
Recensione:
Indirizzi per estratti:
Citazione:
R. Stefanski e S.R. Goldberg, "SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS - POTENTIAL IN THE TREATMENT OF PSYCHIATRIC-DISORDERS", CNS DRUGS, 7(5), 1997, pp. 388-409

Abstract

This review highlights recent pharmacological and clinical advances in the understanding of the potential use of serotonin 5-HT2 receptor antagonists as treatments for a number of psychiatric disorders, namelyanxiety, depression and schizophrenia. 5-HT2 receptor antagonists have not vet been clearly demonstrated to be effective in humans as treatments for anxiety, Some preliminary clinical trials suggest that the 5-HT2 receptor antagonist ritanserin may have a beneficial effect in patients with generalised anxiety disorder, but the evidence is far fromcompelling. Upregulation of central 5-HT2 receptors anti an accompanying increase in phosphoinositide turnover appear to be predisposing biological factors in depression. A functional interaction between 5-HT1A and 5-HT2 receptors mac be of particular importance, since 5-HT2 receptor antagonism can ultimately result in a facilitation of 5-HT1A receptor-mediated neurotransmission and this may be beneficial for the treatment of depression, Ritanserin appears to be more effective than placebo in alleviating the depressive symptoms of dysthymia. Nefazodone is a nets antidepressant that combines 5-HT2 receptor blockade with serotonin reuptake inhibition, Comparisons with imipramine favour nefazodone in terms of tolerability and suggest that both drugs are equally clinical effective, In schizophrenia, 5-HT2A receptor function appearsto be altered. Modulation of dopaminergic function via 5-HT2A receptors may provide a viable mechanism for enhancing the effect of antipsychotics. Risperidone, the first post-clozapine agent that has 5-HT2A and dopamine D-2 receptor antagonist actions, is at least as effective as haloperidol and perphenazine in reducing acute psychotic symptoms. Its major clinical advantages are a greater efficacy in controlling thesecondary negative symptoms and a lower incidence of extrapyramidal symptoms (EPS). The efficacy of ritanserin in alleviating both positiveand negative symptoms in acutely psychotic patients stems to support thr hypothesis that potent 5-HT2A receptor antagonism alone may contribute to the therapeutic action of several clinically effective antipsychotics that have reduced liability to induce EPS.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 15:25:59